Loading patent…
AssigneeThe United States of Americans represented by the Secretary, Department of Health and Human Services
InventorsRichard A. Morgan, Nachimuthu Chinnasamy, Steven A. Rosenberg
Estimating the term…
The invention provides an isolated or purified T cell receptor (TCR) having antigenic specificity for synovial sarcoma X Breakpoint (SSX)-2. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are further provided by the invention.
A recombinant expression vector comprising a nucleic acid comprising a nucleotide sequence encoding a T cell receptor (TCR) having antigenic specificity for synovial sarcoma X Breakpoint (SSX)-2 (SEQ ID NO:
A recombinant expression vector comprising a nucleic acid comprising a nucleotide sequence encoding a polypeptide comprising the amino acid sequences of SEQ ID NOs:
A recombinant expression vector comprising a nucleic acid comprising a nucleotide sequence encoding a protein comprising a first polypeptide chain comprising SEQ ID NO:
Dependencies are inferred from the claim text.